<DOC>
	<DOCNO>NCT00540657</DOCNO>
	<brief_summary>The purpose study determine whether CCX282-B effective mitigating effect gluten ingestion patient celiac disease</brief_summary>
	<brief_title>A Phase II Study CCX282-B Patients With Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Key Male female , 18 75 year age Established diagnosis celiac disease Subject follow strict glutenfree diet least 24 month Key History infection require intravenous antibiotic , serious local infection , systemic infection , gastrointestinal infection within 12 week randomization Use immunosuppressant , TNF inhibitor , natalizumab 12 week prior study randomization Use steroids 4 week prior study randomization Receipt experimental treatment disease within 4 week prior randomization Known IgEmediated atopy allergy anaphylactic reaction gluten The subject suffer condition carry risk endoscopy anticoagulant treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>